Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
My Portfolio
Biocept Inc
(NQ:
BIOC
)
6.030
USD
-0.210 (-3.37%)
Streaming Delayed Price
Updated: 4:11 PM EST, Feb 26, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Biocept Inc
< Previous
1
2
3
4
5
6
7
Next >
Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients
February 23, 2021
Biocept and Protean BioDiagnostics Collaborate to Demonstrate Advantages of Biocept’s Target Selector Assay for Non-Small Cell Lung Cancer Patients.
From
Business Wire News Releases
Study Shows Biocept’s Target Selector™ Detects Mutations in “Quantity Not Sufficient” Specimens in Non-Small Cell Lung Cancer Patients
February 16, 2021
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target Selector™ molecular assay kit detects mutations in up...
From
Business Wire News Releases
Biocept Provides Update on COVID-19 Testing with More than 250,000 Samples Received
February 03, 2021
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, provides an update on its COVID-19 testing with more...
From
Business Wire News Releases
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2021
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve...
From
Business Wire News Releases
Biocept Issues Letter to Stockholders
January 12, 2021
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, announces that President and...
From
Business Wire News Releases
Biocept to Present at H.C. Wainwright Virtual BioConnect Conference
January 04, 2021
CEO Michael Nall to participate in diagnostics and devices panel discussion hosted by former FDA Commissioner Dr. Scott Gottlieb
From
PR Newswire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 31, 2020
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve...
From
PR Newswire
Biocept Enters into Laboratory Services Agreements with Two Southern California Regional Independent Physician Associations
December 30, 2020
Expands physician and patient access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer
From
PR Newswire
Biocept Provides Business Update
December 14, 2020
Announces receipt of more than 150,000 samples for COVID-19 testing and completes relocation to new facility
From
PR Newswire
Biocept's Target Selector™ Liquid Biopsy Demonstrated High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center
December 10, 2020
Using Target Selector™ to detect HER2 alterations assists physicians in reassessing therapy options over the course of treating patients with metastatic breast cancer
From
PR Newswire
While The U.S. Faces Insufficient COVID-19 Testing Volume, EIR Healthcare Launches MedModLabs to Expand Access Immediately
December 01, 2020
Healthcare design innovation firm known for its 'hospital in a box' solution expands modular offerings with new MedModLabs initiative, first rolling out in Philadelphia to help address Pennsylvania's...
From
PR Newswire
Study Shows Biocept's Assays are Viable and Sensitive for Detecting Tumor Cells and Biomarkers in the Cerebrospinal Fluid of Patients with Breast and Lung Cancer that has Metastasized to the Central N
November 20, 2020
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve...
From
PR Newswire
Results from Study Using Biocept's Target Selector™ Testing to Monitor Breast Cancer Disease Progression to be Presented at 2020 SABCS®
November 17, 2020
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve...
From
PR Newswire
Biocept Reports Third Quarter 2020 Financial Results
November 12, 2020
Revenues of $6.6 million - a result of decision to offer COVID-19 testing
From
PR Newswire
Thinking about buying stock in IMAC Holdings, Advanced Micro Devices, Biocept, Li Auto, or EuroDry?
November 12, 2020
InvestorsObserver issues critical PriceWatch Alerts for IMAC, AMD, BIOC, LI, and EDRY.
From
PR Newswire
Biocept Provides Update on COVID-19 Testing with More than 100,000 Samples Received
November 12, 2020
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with...
From
PR Newswire
Biocept Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells
November 09, 2020
Further expands global patent estate for capturing and detecting rare cells of interest, including CTCs, to aid in the treatment of patients with cancer
From
PR Newswire
Biocept Awarded Broad Japanese Patent for the Use of Binding Entities in Combination with any Solid Surface to Capture and Detect any Target of Interest, including CTCs, from any Sample Type
November 05, 2020
Biocept further expands its patent estate for capturing and detecting target cells of interest, including CTCs
From
PR Newswire
Biocept to Release Third Quarter 2020 Financial Results and Host Investor Conference Call on November 12, 2020
November 04, 2020
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients, announces that it will release financial results for the...
From
PR Newswire
Biocept Provides Update on COVID-19 Testing with More than 80,000 Samples Received
October 29, 2020
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with...
From
PR Newswire
Biocept Appoints Samuel D. Riccitelli to its Board of Directors
October 21, 2020
Diagnostic industry veteran plans immediate start
From
PR Newswire
Biocept Provides Update on COVID-19 Testing with More than 50,000 Specimens Received
October 06, 2020
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces it has received more than 50,000 COVID-19...
From
PR Newswire
Study Shows Biocept's Target Selector™ May Provide a More Robust Method for Detecting Lung Cancer Metastasis in Cerebrospinal Fluid than Cytology
October 05, 2020
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients, announces results from a prospective study comparing its...
From
PR Newswire
Biocept to Present Study Results from Target Selector™ Testing in the Cerebrospinal Fluid of Patients with Lung Cancer at the IASLC Liquid Biopsy Meeting
October 01, 2020
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve...
From
PR Newswire
Biocept Announces the Award of Japanese Patent for Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Cell Mutations in Tissue, Blood and Cerebrospinal Fluid
September 23, 2020
Further expands Company's patent portfolio in pursuit of worldwide intellectual property protection for Primer-Switch technology for the field of oncology
From
PR Newswire
Aegea Biotechnologies, Inc. Announces the Award of Japanese Patent for Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Genetic Alterations and Variants
September 23, 2020
Further expands Company's patent portfolio in pursuit of worldwide intellectual property protection for Primer-Switch technology; Applicable to Coronavirus (COVID-19) Molecular Diagnostic Testing
From
PR Newswire
Thinking about buying stock in Avadel Pharmaceuticals, Nikola Corp, Agile Therapeutics, Biocept Inc, or Uber Technologies?
September 21, 2020
InvestorsObserver issues critical PriceWatch Alerts for AVDL, NKLA, AGRX, BIOC, and UBER.
From
PR Newswire
Biocept Announces that Highmark Has Made a Positive Coverage Determination on Target Selector™ Liquid Biopsy
September 21, 2020
Two-year evaluation in advanced lung cancers at Allegheny Health Network demonstrated improved access to optimal treatment while reducing healthcare costs
From
PR Newswire
Thinking about buying stock in Pacific Ethanol, Inovio Pharmaceuticals, Scientific Games, Biocept, or Delta Air Lines?
September 16, 2020
InvestorsObserver issues critical PriceWatch Alerts for PEIX, INO, SGMS, BIOC, and DAL.
From
PR Newswire
Biocept Provides COVID-19 Testing Update with More than 35,000 Specimens Received
September 16, 2020
Announces distribution of approximately 83,000 specimen collection kits to clients
From
PR Newswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.